Naomi B. Haas, MD
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Director, Prostate and Kidney Cancer Program, University of Pennsylvania
Co-Leader of the Cancer Therapeutics Program, Abramson Cancer Center
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor South Pavilion
Office #10-112
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor South Pavilion
Office #10-112
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-7402
Education:
B.S. (Integrated Life Sciences)
Kent State University, 1985.
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
Permanent linkB.S. (Integrated Life Sciences)
Kent State University, 1985.
M.D.
Northeastern Ohio Universities College of Medicine, 1985.
Description of Clinical Expertise
I am an international expert in the conduct and design of adjuvant clinical trials for kidney cancer.I am a national expert in prostate and kidney cancer therapeutics.
Selected Publications
Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD.: Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. Diabetes Care 37(7): 1910-7, Feb 2014 Notes: DOI: 10.2337/dc13-1489.Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A.: Phase II trial of Vorinostat in advanced melanoma. Invest New Drugs 32(3): 526-34, Jan 2014 Notes: ISSN 0167-6997.
Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. : Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4): 412-9, Feb 2013.
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. : Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 31(2): 181-6, Jan 2013 Notes: DOI: 10.1200/JCO.2012.43.3383.
Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N. : Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. Int J Radiat Oncol Biol Phys 83(5): 1493-9, Aug 2012 Notes: DOI: 10.1016/j.ijrobp.2011.10.047.
Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J.: A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. (Northwood, London, England) 29(2): 761-7, Jun 2012.
Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE.: Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 83(1): 8-15, May 2012.
Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE.: Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 83(1): 8-15, May 2012.
Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE. : Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. Urology. Nov 2011.
Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE.: Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. Urology. 78(5): 1107-13, Nov 2011.